Table 5.
Outcomes Reported for Individual Studies.
| Study | Outcome | Threshold | Main Outcome used in Meta-Analysis | Value of Outcome | Adjustments |
|---|---|---|---|---|---|
| Manning 2002(32) | Albumin-to-creatinine ratio (mg/g Cr) | 30 mg/g Cr | Median (IQR) range of change from baseline to end of intervention | Median (IQR) of changea HT: 2 (-11, 21) Placebo: 2 (-1, 14) |
None |
| Machado 2008(30) | Urine albumin excretion (μg/min) by 12 hour collection | N/A | Mean change in microalbuminuria from baseline to follow-up | Mean (SD) of change HT: -0.16 (2.79) Placebo: -0.86 (3.64) |
None |
| Yilmaz 2011(31) | Microalbumin (mg/L) | N/A | Mean change in microalbuminuria from baseline to follow-up | Mean (SD imputed)b of change HT: -11.5 (24.3) Placebo: -8.2 (18.3) |
None |
| Szekac 2000(24) | 24-hour urine protein (mg/24 hrs) | N/A | Mean change in proteinuria from baseline to follow-up | Mean (SD) of pre- and post-HT Pre-HT: 452(39) Post-HT: 370 (47) |
None |
| Monster 2000(9) | Microalbuminuria | 30-300 mg/g Cr | Odds Ratio – adjusted | OR (95% CI): 2.05 (1.12-3.77) | Age, HTN, DM, obesity, hyperlipidemia, smoking |
| Fencki 2003(23) | 24-hour urine protein (mg/24 hrs) | N/A | Mean change in proteinuria from baseline to follow-up (combined HT and DM) | Mean (SD) of pre- and post-HT Pre-HT: 125.9 (31.9) Post-HT: 142 (21.3) |
None |
| Agarwal 2005(11) | Albumin-to-creatinine ratio (mg/g Cr) | 25 mg/g Cr | Odds Ratio – adjusted | OR (95% CI): Prospective: OR 0.67 (0.43-1.01) Mean (SD) of ln (UACR) HT: 2.16 (0.82) No HT: 2.43 (1.07) |
Age, race, DM, SBP, DBP, triglycerides, HDL, smoking, BMI, GFR |
| Schopick 2009(12) | Top albumin-to-creatinine ratio decile | 9.2 mg/g Cr | Odds Ratio – adjusted | OR (95% CI): 0.55 (0.39-0.77) Median (IQR) of two groups: HT (> 6 years): 2.58 (1.6-4.6)c No HT: 3.5 (2.1-5.8) |
Age, BMI, hypertension and eGFR |
| Fung 2011(10) | Albumin-to-creatinine ratio (mg/g Cr) | 25 mg/g Cr | Odds Ratio - adjusted | Cross-sectional: OR 1.07 (0.73-1.56) Prospective: Mean (SD imputed)b change of ln(UACR) HT: -0.07 (0.8) No HT: 0.31 (0.77) |
Age, weight, DM, smoking, hyperlipidemic, HTN Age |
| Kaygusz 2012(41) | Protein-to-creatinine ratio | N/A | Difference in mean between HT and no HT group | Median (IQR) of two groupsa: HT: 0.08 (0.01-0.97) No HT: 0.09 (0-0.6) |
None |
| Vitolo 2015(42) | Albumin-to-creatinine ratio (mg/g Cr) | N/A | Odds Ratio – unadjusted | OR (95% CI): 0.90 (0.549-1.479) Median (IQR) of two groupsa: HT: 6.45 (2.16-29.1) No HT: 6.15 (2.70-33.9) |
None |
a
Median taken as mean change and interquartile range converted to standard deviation of change for analysis of continuous outcomes.
b
Standard deviation of change imputed using the correlation coefficient calculated from Machado et al (correlation coefficient = 0.53).
c
Combined medians of all groups with > 6 years of hormone therapy and took widest confidence interval for the group.
Abbreviations: Cr = creatinine, IQR = interquartile range, HT = hormone therapy, SD = standard deviation, N/A = not applicable, HTN = hypertension, DM = diabetes, BMI = body-mass index, OR = odds ratio, CI = confidence interval, UACR = urine albumin-to-creatinine ratio